NDC codes

FDA NDC Directory
Product NDC (as listed)75907-166Labeler and product segments. Claims need a package NDC.
Product NDC at billing width75907-0166Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
75907-166-0175907016601100 CAPSULE in 1 BOTTLE (75907-166-01)Marketed from May 30, 2025
75907-166-307590701663030 CAPSULE in 1 BOTTLE (75907-166-30)Marketed from May 30, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Metyrosine
Generic name (nonproprietary)
metyrosine
Active ingredients
Metyrosine — 250 mg/1
Dosage form
Capsule
Route
Oral
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 218620
Marketing start
Listing expires
Other FDA classes
Catecholamine Synthesis Inhibitors (Mechanism)
Identifiers
Product ID 75907-166_cd87ec4e-09e2-40d7-831b-0b2e5205dafaSPL ID cd87ec4e-09e2-40d7-831b-0b2e5205dafaSPL set ID 1b7897b4-7681-4b99-8883-d5dc33f86c01RxCUI 197980UNII DOQ0J0TPF7UPC 0375907166303
Pharmacologic class
Catecholamine Synthesis Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N475907016601 followed by a unit qualifier and the quantity

Package 75907-0166-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

INDICATIONS AND USAGE Metyrosine capsules are indicated in the treatment of patients with pheochromocytoma for: Preoperative preparation of patients for surgery Management of patients when surgery is contraindicated Chronic treatment of patients with malignant pheochromocytoma Metyrosine capsules are not recommended for the control of essential hypertension.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in